PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.68%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
9.32%
Gross profit growth above 1.5x MRVL's 3.82%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
43.39%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
33.50%
Operating income growth above 1.5x MRVL's 15.99%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
15.24%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
20.00%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
20.00%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
45.37%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
42.90%
Diluted share count expanding well above MRVL's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
-33.23%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-24.69%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-19.83%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-33.03%
Negative 10Y revenue/share CAGR while MRVL stands at 56.20%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-57.43%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-63.08%
Negative 3Y CAGR while MRVL stands at 25.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-37.86%
Negative 5Y OCF/share CAGR while MRVL is at 45.44%. Joel Greenblatt would question the firm’s operational model or cost structure.
-46.80%
Negative 3Y OCF/share CAGR while MRVL stands at 63.72%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
12.76%
Below 50% of MRVL's 653.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-27.94%
Negative 5Y net income/share CAGR while MRVL is 220.76%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-56.65%
Negative 3Y CAGR while MRVL is 202.86%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
115.41%
10Y equity/share CAGR above 1.5x MRVL's 54.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
42.97%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
6.40%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
29.25%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
-1.57%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-33.25%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-2.35%
Firm’s AR is declining while MRVL shows 11.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
8.42%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.96%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-25.51%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.07%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-3.44%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
5.47%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.